Peripheral Hemolysis in Relation to Iron Rim Presence and Brain Volume in Multiple Sclerosis.

Background

Iron rim lesions (IRLs) represent chronic lesion activity and are associated with a more severe disease course in multiple sclerosis (MS). How the iron rims around the lesions arise in patients with MS (pwMS), and whether peripheral hemolysis may be a source of iron in rim associated macrophages, is unclear.

Objective

To determine a potential correlation between peripheral hemolysis parameters and IRL presence in pwMS.

Methods

This retrospective study included pwMS, who underwent a 3T brain MRI between 2015 and 2020 and had a blood sample drawn at ± 2 weeks. Patients with vertigo served as a control group.

Results

We analyzed 75 pwMS (mean age 37.0 years [SD 9.0], 53.3% female) and 43 controls (mean age 38.3 years [SD 9.8], 51.2% female). Median number of IRLs was 1 (IQR 4), 28 (37.3%) pwMS had no IRLs. IRL patients showed significantly higher Expanded Disability Status Scale (EDSS) compared to non-IRL patients (median EDSS 2.3 [IQR 2.9] vs. 1.3 [IQR 2.9],

Conclusion

Our data do not suggest an association between hemolysis parameters and IRL presence despite a significant association between these parameters and markers for neurodegeneration.

Informations de copyright

Copyright © 2022 Krajnc, Bsteh, Kasprian, Zrzavy, Kornek, Berger, Leutmezer, Rommer, Lassmann, Hametner and Dal-Bianco.

Déclaration de conflit d'intérêts

NK has participated in meetings sponsored by, received speaker honoraria or travel funding from Celgene/BMS, Merck, Novartis, Roche and Sanofi-Genzyme, and held a grant for a Multiple Sclerosis Clinical Training Fellowship Programme from ECTRIMS. GB has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Celgene/BMS, Lilly, Merck, Novartis, Roche, Sanofi-Genzyme and Teva, and received honoraria for consulting Biogen, Celgene/BMS, Novartis, Roche, Sanofi-Genzyme and Teva. He has received financial support in the past 12 months by unrestricted research grants Celgene/BMS, Novartis. GK has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, and received honoraria for consulting from Biogen. TZ has participated in meetings sponsored by or received travel funding from Biogen, Merck, Novartis, Roche, Sanofi-Genzyme and Teva. BK has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Celgene/BMS, Janssen, Merck, Novartis, Roche, Sanofi Genzyme and Teva, and received honoraria for consulting Biogen, Celgene/BMS, Merck, Novartis, Roche, Sanofi-Genzyme and Teva. TB has participated in meetings sponsored by and received honoraria lectures, advisory boards, consultations from pharmaceutical companies marketing treatments for MS: Allergan, Allmiral, Bayer, Biogen, Bionorica, Celgene/BMS, GSK, Janssen-Cilag, MedDay, Merck, Novartis, Octapharma, Roche, Sandoz, Sanofi-Genzyme, Teva. His institution has received financial support in the past 12 months by unrestricted research grants Biogen, Bayer, Celgene/BMS, Merck, Novartis, Sanofi Aventis, Teva and for participation in clinical trials in multiple sclerosis sponsored by Alexion, Bayer, Biogen, Merck, Novartis, Octapharma, Roche, Sanofi-Genzyme, Teva. FL has participated in meetings sponsored by and received honoraria lectures, advisory boards, consultations from pharmaceutical companies marketing treatments for MS: Actelion, Allmiral, Bayer, Biogen, Celgene, MedDay, Merck, Novartis, Octapharma, Roche, Sanofi-Genzyme, Teva-Ratiopharm. PR has received honoraria for consultancy/speaking from AbbVie, Allmiral, Alexion Astra Zeneca, Biogen, Merck, Novartis, Roche, Sandoz, Sanofi Genzyme, has received research grants from Amicus, Biogen, Merck, Roche. HL has received honoraria for lectures from Novartis, Biogen, ROCHE, Merck and Sanofi Aventis. SH has participated in meetings sponsored by or received speaker honoraria or travel funding from Biogen and Sanofi-Aventis. AD-B position as junior group leader for Translational Morphology in Neuroscience was supported by a research grant from Biogen. She has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Celgene BMS, Merck, Novartis, Roche and Sanofi; and has received an unrestricted grant from Merck GmbH, an affiliate of Merck KGaA.